Risankizumab-associated lichen planus pemphigoides.

Biological agents are generally safe and effective drugs used in the treatment of moderate-to-severe psoriasis.1 There are reports of cutaneous drug reactions, including drug-induced bullous pemphigoid (DBP),2 associated with biologics. The biologics anti–tumor necrosis factor-α (TNF-α) and anti-interleukin (IL) 12/23 stand out as being more frequent causative agents, with 8 reports of DBP in patients receiving TNF-α inhibitors and 6 reports in patients receiving IL-12/23 inhibitors.3 However, there are only 2 reports of IL23-inhibitor–induced bullous pemphigoid (BP), only 1 of which was associated with risankizumab.